Multicenter Study to Evaluate the Safety and Efficacy of MK-0518 [raltegravir] in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance

Trial Profile

Multicenter Study to Evaluate the Safety and Efficacy of MK-0518 [raltegravir] in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2010 96-week results published in the Journal of Acquired Immune Deficiency Syndromes.
    • 30 Oct 2009 144-week results of open-label extension presented at the 47th Annual Meeting of the Infectious Diseases Society of America.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top